193 related articles for article (PubMed ID: 32661806)
1. Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.
Attia DHS; Eissa M; Samy LA; Khattab RA
Clin Rheumatol; 2021 Feb; 40(2):753-762. PubMed ID: 32661806
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.
Audemard-Verger A; Martin Silva N; Verstuyft C; Costedoat-Chalumeau N; Hummel A; Le Guern V; Sacré K; Meyer O; Daugas E; Goujard C; Sultan A; Lobbedez T; Galicier L; Pourrat J; Le Hello C; Godin M; Morello R; Lambert M; Hachulla E; Vanhille P; Queffeulou G; Potier J; Dion JJ; Bataille P; Chauveau D; Moulis G; Farge-Bancel D; Duhaut P; Saint-Marcoux B; Deroux A; Manuzak J; Francès C; Aumaitre O; Bezanahary H; Becquemont L; Bienvenu B
PLoS One; 2016; 11(3):e0151696. PubMed ID: 27002825
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
[TBL] [Abstract][Full Text] [Related]
4. The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients.
Wang HN; Zhu XY; Zhu Y; Xie QH; Lai LY; Zhao M; Chen YC; Xue J; Hao CM; Gu Y; Lin SY
Clin Immunol; 2015 Oct; 160(2):342-8. PubMed ID: 26222310
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
6. Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the FCGR2B-FCRLA Locus.
Kim K; Bang SY; Joo YB; Kim T; Lee HS; Kang C; Bae SC
J Rheumatol; 2016 Jun; 43(6):1045-9. PubMed ID: 26980576
[TBL] [Abstract][Full Text] [Related]
7. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
[TBL] [Abstract][Full Text] [Related]
8. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms effect on cyclophosphamide's tolerability and clinical efficacy in Egyptian patients with lupus nephritis.
Abuelsoud NN; El Khateeb EM
Pharmacogenet Genomics; 2023 Oct; 33(8):172-180. PubMed ID: 37611146
[TBL] [Abstract][Full Text] [Related]
10. High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis.
Elaziz MMA; Gamal SM; Fayed A; Abu-Zaid MH; Ghoniem SA; Teleb DA
Z Rheumatol; 2024 Feb; 83(Suppl 1):115-123. PubMed ID: 37582953
[TBL] [Abstract][Full Text] [Related]
11. Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis.
Indrawijaya YYA; Hamijoyo L; Artarini AA; Iwo MI
Acta Med Indones; 2023 Jul; 55(3):343-349. PubMed ID: 37915145
[TBL] [Abstract][Full Text] [Related]
12. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
13. Interferon regulatory factor 5 gene polymorphism in Egyptian children with systemic lupus erythematosus.
Hammad A; Mossad YM; Nasef N; Eid R
Lupus; 2017 Jul; 26(8):871-880. PubMed ID: 28059021
[TBL] [Abstract][Full Text] [Related]
14. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphism T869C of transforming growth factor-beta 1 gene and systemic lupus erythematosus: association with disease susceptibility and lupus nephritis.
Sayed SK; Galal SH; Herdan OM; Mahran AM
Egypt J Immunol; 2014; 21(2):9-21. PubMed ID: 25812349
[TBL] [Abstract][Full Text] [Related]
16. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
17. Association of Osteopontin gene single nucleotide polymorphism with lupus nephritis.
Metwally RM; Hasan AS; R EG
Int J Rheum Dis; 2022 May; 25(5):571-575. PubMed ID: 35218609
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
19. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
20. Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Kumaraswami K; Katkam SK; Aggarwal A; Sharma A; Manthri R; Kutala VK; Rajasekhar L
Pharmacogenomics; 2017 Oct; 18(15):1401-1411. PubMed ID: 28976264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
